Home > News > Detailed Positive ABRAXANE Phase III Data Released
December 8th, 2003
Detailed Positive ABRAXANE Phase III Data Released
American Pharmaceutical Partners, Inc. and ABRAXIS Oncology, the proprietary drug division of APP, today announced positive results of the randomized, controlled Phase III clinical trial in patients with metastatic breast cancer comparing the investigational product ABRAXANE(TM) to the CremophorŽ solvent-based TAXOLŽ. Patients with metastatic breast cancer receiving the solvent-free nanoparticle paclitaxel, ABRAXANE achieved almost a doubling of the tumor response rate when compared to those patients receiving Bristol-Myers Squibb's TAXOLŽ.
Production of Biocompatible Polymers in Iran October 30th, 2014
Amorphous Coordination Polymer Particles as alternative to classical nanoplatforms for nanomedicine October 30th, 2014
'Electronic skin' could improve early breast cancer detection October 29th, 2014
Tiny carbon nanotube pores make big impact October 29th, 2014